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To assess the level of concordance with international consensus on asthma management, we compared primary care
prescribing patterns for asthma in dierent European countries.
A prospective study of prescription items with an associated diagnostic label of asthma in patient consultations
with a total of 235 general practitioners (GPs) from Belgium, England, Ireland, Italy, Northern Ireland, Portugal,
Scotland and Spain was performed. A total of 101 544 consecutive consultations were recorded in autumns 1994
and 1995 of which 3595 (35%) were for patients with asthma and 3243 (32%) were for patients receiving a
prescription for asthma.
Overall, asthma consultations varied from 18% in Italy to 58% in Ireland (mean 34%, SD 16). Prescribed
inhaled medications for children varied from 72% of the total asthma prescriptions in Ireland and Portugal to 82%
in Northern Ireland (mean 79%, SD 81) and for adults 55% in Italy to 85% in Spain (mean 70%, SD 10). Inhaled
corticosteroid usage for adults varied from 14% in Italy to 31% in Northern Ireland (mean 24%, SD 64). For
children, b2-agonist use varied from 24% in Italy to 67% in Spain (mean 45%, SD 13).
Despite publication of international guidelines for the management of asthma, inter-country prescribing practices
vary considerably and could be improved. The frequency of use of asthma as a diagnostic label also varies
markedly.
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High levels of asthma morbidity and mortality have been
shown in many countries ( 1–8 ). National prevalences of
asthma symptoms in children have been found to vary
widely from 16% in Indonesia to 368% in the U.K. (9).
Under-treatment has been acknowledged as a problem in
several European countries (10–16) and beyond (7,17–19).
Despite under-diagnosis and under-treatment, the require-
ment for prescriptions in asthma care is massive—in the
U.K. about 7% of all National Health Service (NHS)
prescriptions are for asthma (20). The total annual cost of
asthma in the U.K. in 1990 was estimated to be between 322
and 686 million pounds (21), 20–25% of the direct costs
being due to hospitalization.
Following international consensus on asthma manage-
ment (22), it is reasonable to hope that prescribing in the
community should be in line with recognized guidelines toReceived 9 August 1999 and accepted in revised form 3 January
2000.
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prescribing patterns for asthma in dierent western
European countries by gathering prospectively details of
diagnoses made and drug items prescribed in the practices
of general practitioners (GPs) over two distinct time periods
in the mid 1990s.
Patients and methods
This research emerged from a 3-year BIOMED-funded
study to investigate the eect of a consensus-based
European Formulary (EF) for general practice, together
with an educational intervention promoting the rational
prescribing of specific drug groups, namely antibiotics and
non-steriodal anti-inflammatory drugs (NSAIDs) (23,24).
The study used a multi-national, prospective randomized
controlled methodology. After an international conference
in 1987, a group of approximately 50 members from 17
European countries compiled a draft European Formulary
to cover the majority of conditions presenting in general
practice.
Ethical permission for this study was not required since
patients’ medical care was not being adversely aected and
the intervention only involved the doctors concerned.# 2000 HARCOURT PUBLISHERS LTD
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The subjects were patients with asthma consulting with
and receiving prescribed medication from GPs within six
European countries, namely Belgium, Ireland, Italy, Portugal,
Spain and the U.K. (consisting of three participating centres:
England; Northern Ireland and Scotland). Of the eight
centres, each had an active member on the EF development
group who acted as a national co-ordinator under the central
guidance of a research team in Newcastle, U.K.
STUDY DESIGN
The research was a prospective study of prescription items
with an associated diagnostic label of asthma in patient
consultations with GPs.
METHODS
Each co-ordinator recruited up to 40 volunteer GPs in their
countries prior to being randomly allocated to either a
study group, which received the EF and an associated
educational programme focusing on antibiotic and NSAID
prescribing or to a control group, receiving neither.
Participating doctors were asked to record data for two
periods, the first time period was in the autumn of 1994 and
the second time period in the autumn of 1995. The GPs who
were part of the study group received the educational
intervention prior to the second time period.
Information was requested from consecutive face-to-face
consultations, until a total of 200 resulting in a prescription
had been reached. Variables included: patient age, patient
gender, patient diagnosis(es), drug name, single entity or
combination preparation and the category/origin of the
script. The doctors were asked to record a diagnosis for
every drug prescribed.
Completed data sets (translated where necessary) were
sent to Newcastle for manual coding and data entry. The
drug coding frame was based on the British Read Codes
Classification system (25) and additional drug entities were
added in appropriate therapeutic sections as coding
progressed. The diagnosis coding frame consisted of the
diagnoses covered by the Formulary and subsequent
non-Formulary diagnoses. The latter were added after
consultation with the ninth revision of the International
Classification of Diseases (26). Asthma was covered by the
EF but since the educational intervention did not focus on
this area, all the asthma consultation data before and after
the intervention were considered together. No time trends
between the two periods were found in terms of con-
cordance with the EF so the whole data set is considered
together.
ANALYSIS
Outcome measures examined by country include: percen-
tage of asthma diagnoses, inhaled medication use, patterns
of inhaled corticosteroids, patterns of b2-agonist broncho-
dilators and other prescriptions for asthma. Data arepresented for children (15 years and under) and separately
for adults (16 years and over). Statistical analysis used the
SPSS 70 statistical analysis package (27). Descriptive
statistics are presented with comparisons between countries
using analysis of variance.
Results
The data set as a whole comprised 101 544 consultations
from 235 doctors, ranging from 10 doctors in Belgium to 40
doctors in Italy and Scotland. The mean number of doctors
per country was 27. Overall, asthma was the sixth most
common diagnosis, accounting for 35% of the total
number of consultations in general practice. The frequency
of asthma consultations (Table 1) in each country varied
from 18% in Italy to 58% in Ireland (mean 34%, SD 16).
Using the number of patient consultations as a proxy for
the number of patients seen (it was clearly possible for a
single patient to be seen on more than one occasion), the
percentage of treated asthma patients on inhaled corticos-
teroids for all ages combined (Table 1) varied from 23% in
Italy to 48% in Spain (mean 37% SD 99). The proportion
of total items prescribed in children 0–15 years which
prescribed items for asthma represent (Table 2), varied
from 32% in Portugal to 17% in Ireland and Northern
Ireland (mean 10% SD 55) and in adults 16 years and above
this varied from 18% in Portugal to 5.3% in Ireland (mean
31% SD 13).
CHILDREN
Prescribed inhaled medications varied from 72% of all
prescribed items for asthma in Ireland and Portugal to 82%
in Northern Ireland (mean 79%, SD 81) (Table 3). Inhaled
corticosteroid usage varied from 12% in Portugal to 34% in
Northern Ireland (mean 22%, SD 80). Use of individual
corticosteroids also varied widely; Spain used no beclo-
methasone, instead using budesonide in 28% of asthma
prescriptions. Northern Ireland used fluticasone in 45%—
more than three times the frequency in any other country.
In all other countries beclomethasone was predominantly
the steroid of choice accounting for 15% of all asthma
prescriptions. b2-agonist use (long- and short-acting com-
bined) varied from 24% of all prescribed items for asthma
in Italy to 67% in Spain for children (mean 45%, SD 13).
Combination drug items accounted for less than 13% of
asthma prescriptions for children. Cromoglycate use alone
varied from 0% in Spain to 73% in Italy (mean 36%,
SD 27). Methylxanthine use varied from none in England to
88% in Ireland (mean 38%, SD 30). Antibiotic prescribing
in children at consultations for asthma varied from none in
Spain and Portugal to 73% in Belgium (mean 29%, SD 25).
ADULTS
Prescribed inhaled medications varied from 55% in Italy to
85% in Spain (mean 70%, SD 10) (Table 4). Inhaled
corticosteroid usage varied from 14% in Italy to 31% in
TABLE 1. Overall number of participating GPs and patient consultations, number and percentage of patient consultations for
asthma, proportion of asthma patients receiving treatment for their condition and percentage of (treated) patients receiving
inhaled corticosteroids
Country No.
GPs
No of patient
consultations{
Total No (%) patient
consultations for asthma
Mean % (SEM) asthma
patients with a prescription
for asthma
% of treated asthma
patients receiving inhaled
corticicosteroids
Belgium 10 3829 89 (23)* 100 (–)* 46
England 27 14 629 622 (42) 8 (16) 40
Ireland 35 16 508 965 (58) 94 (14) 31
Italy 40 17 741 324 (18) 94 (27) 23
N. Ireland 13 6809 351 (52) 87 (22) 47
Portugal 39 10 674 204 (19) 98 (10) 30
Scotland 40 20 980 811 (39) 84 (20) 27
Spain 31 10 374 229 (22) 98 (07) 48{
ANOVA P<00001 P<00001
{Some GPs fell short of recording consecutive face to face consultations until 200 had resulted in a prescription.
*Belgium data was excluded from this analysis as it did not include consultations where a prescription was not given.
{In Spain the formulation of budesonide was unclear, it was assumed to be inhaled.
TABLE 2. Number of items prescribed for asthma per country and the percentage of the total items prescribed
Country Belgium England Ireland Italy N. Ireland Portugal Scotland Spain
Prescribed items for asthma in
children 0–15 years (% of total
items prescribed)
41 (38) 273 (11) 568 (17) 41 (61) 223 (17) 52 (32) 322 (11) 18 (14)
Prescribed items for asthma in
adults 16 years and above (%
of total items prescribed)
161 (26) 534 (42) 923 (53) 430 (19) 217 (35) 346 (18) 646 (35) 364 (2)
TABLE 3. Asthma prescribing by drug group in terms of the number of items prescribed per country in children 0–15 years
Country
Drug Group Belgium England Ireland Italy N. Ireland Portuga Scotland Spain
No. prescribed items for asthma 41 273 568 41 223 52 322 18
Short acting b2-agonists 12 139 286 10 105 19 147 10
Long acting b2-agonists 3 6 0 0 7 0 4 2
Inhaled corticosteroids 6 68 73 8 76 6 86 5
Oral corticosteroids 1 27 66 2 17 2 36 0
Cromoglycate and related therapy 5 2 43 14 4 12 12 0
Antimuscarinics 4 2 4 0 2 0 1 0
Methylxanthines 2 0 50 1 3 3 4 1
Antibiotics 3 8 27 1 4 0 12 0
Asthma appliances 0 20 7 0 2 0 18 0
All other drugs prescribed for asthma 5 1 12 5 3 10 2 0
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beclomethasone in 6% of asthma prescriptions but
budesonide in 22% and Northern Ireland used beclometha-
sone in 16% but budesonide in 13%. In all other countriesbeclomethasone was again predominantly the steroid of
choice, accounting for 17% of asthma prescriptions overall.
b2-agonist use (long- and short-acting combined) varied
from 27% in Belgium to 48% in Spain (mean 40%, SD 70).
TABLE 4. Asthma prescribing by drug group in terms of the number of items prescribed per country in adults 16 years and
above
Country
Drug Group Belgium England Ireland Italy N. Ireland Portugal Scotland Spain
No. prescribed items for asthma 161 534 923 430 217 346 646 364
Short acting b2-agonists 39 234 374 110 84 128 265 146
Long acting b2-agonists 4 14 10 39 8 3 14 27
Inhaled corticosteroids 35 151 209 60 68 53 182 102
Oral corticosteroids 10 74 104 33 41 11 102 15
Cromoglycate and related therapy 6 6 15 21 0 14 8 21
Antimuscarinics 17 11 52 4 4 7 12 12
Methylxanthines 28 4 107 98 5 68 7 19
Antibiotics 5 17 31 16 6 2 32 6
Asthma appliances 0 20 4 0 1 0 17 0
All other drugs prescribed for asthma 17 3 13 49 0 60 7 16
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than 64% of prescription items for asthma. Methyl-
xanthine use varied from 08% in England to 23% in Italy
(mean 102%, SD 90). Antibiotic prescribing for adults
varied from 06% in Portugal to 50% in Scotland (mean
29%, SD 1.3).
Discussion
Despite international consensus on asthma management
(22), patterns of asthma prescribing in general practice vary
considerably, as does the frequency of asthma diagnosis. If
prescribing were more in concordance with published
guidelines (28,29), one would expect more consistent
asthma treatment, minimal antibiotic use and no prescrib-
ing of drugs of limited clinical value. The variation in
proportions of patients with asthma suggests that there may
well be dierences in the labelling of asthma as indicated by
other studies (12,15,30,31).
Some cautions should be considered in interpreting these
data. Firstly is the volunteer nature of the participating
GPs. Co-ordinators were asked to recruit up to 40 such
doctors as it was not deemed possible to obtain a random
sample in each of the participating countries. Despite the
data recording task, there was no financial incentive to
encourage the GPs to participate. However, any potential
bias occurring as a consequence of recruiting more
enthusiastic GPs would have tended to produce artificially
good results and so the levels of drug utilization found
would be likely to reflect more informed rather than
average use, thus underestimating the variations that exist.
Secondly, the information on diagnoses and drugs
prescribed was only collectable at the time of the consulta-
tion and so we were unable to check the quality of the data
collated. Other diculties were introduced as a result of
this, including, for example, that the doctors’ record sheets
were not always legible. Some of the apparently morebizarre drugs prescribed for asthma may in fact have
reflected co-morbid prescribing, thus creating an artificial
link with a diagnosis of asthma.
Thirdly, another important confounder is the dierence
in organization of general practice in the various countries
and the dierence in distribution of asthma patients
between the primary and secondary care sector, which
make it dicult to compare the patient populations in the
various countries.
Lastly, in the calculation of the percentage of patients
receiving inhaled corticosteroids (Table 1)—a potential
quality marker—the number of treated asthma patients was
used in order to enable comparison with the Belgian data.
In addition, presenting the ratio between prescribed b2-
agonists compared with the country’s total percentage for
inhaled drugs would not have been an entirely accurate
measure as a small proportion of b2-agonists may have
been oral formulations.
The results detailed are not easily comparable with other
published studies as the drug and morbidity data presented
are solely based on consecutive face-to-face consultations
with GPs. There was a highly significant dierence in the
mean percentage of patients consulting GPs with asthma
between countries. Despite the variation in the number of
participating GPs between the countries (Table 1), similar
trends of high prevalence in the U.K. and Ireland and low
in the Mediterranean countries have been reported
(9,31,32). Dierent studies have varying methods of data
collection, sample sizes and age groups, with some studies
relying only on GP and patient recall and/or question-
naires. Whilst this study avoided these sources of bias, we
recognize that there remains a problem with GP-labelled
asthma diagnosis in all such studies. We acknowledge that
variations in labelling may have varying eects on
prescribing patterns but our study did not permit examina-
tion of this.
The levels of inhaled drug use appear to be high in all
the countries for children. In adults, there appears to be a
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countries, with high levels in the U.K. centres and low
levels in the other countries. There was a low prevalence of
inhaled steroids (both for children and adults) in Italy with
a high prevalence in the U.K., which is consistent with data
reported in the ECRHS (32). Inhaled bronchodilator use is
also broadly similar between our study and the ECRHS.
For antibacterial drugs, higher levels were found to be
prescribed for children in Belgium and Ireland and for
adults in Scotland followed by Italy. Antibacterial drug
prescribing for asthma is considered to be irrational (33).
Higher levels of ‘all other drugs prescribed for asthma’
(largely consisting of drugs of limited clinical value: cough
suppressants; expectorants; mucolytics; sympathomimetic
decongestants) were seen in Belgium, Italy and Portugal
and may also be perceived as indicators of inappropriate
prescribing.
Overall, prescribing trends for adults, particularly in
Belgium, Italy and the U.K. centres appear to be similar to
the ECRHS results in the majority of these drug group
areas.
The therapeutic management of asthma should now be
relatively straight-forward, although many challenges
remain in its organizational management, especially in the
long-term. However, it is known that the mere publication
of guidelines, whether disease-specific or as formularies to
guide prescribing, does not revolutionize therapeutics in the
community (34). U.K. evidence on the actual management
of a large number of asthma attacks in primary care after
the publication of guidelines showed marked deficiencies
(35). For instance, antibiotics were prescribed by GPs in
32% of attacks (35).
The considerable variation in most aspects of asthma
prescribing between the countries sampled in this study
suggests that there is still much room for improvement. If
our results could be corroborated on a larger scale, co-
ordinated eorts to improve asthma care across Europe
would appear to be necessary.
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